Cardiff Lexington Announces Third Quarter 2026 Financial Results
Key Highlights
- ➤Nine-month revenue $6.29 million, down from $8.76 million year-over-year
- ➤Nine-month net loss $8.78 million versus $2.82 million year-over-year
- ➤Nine-month adjusted EBITDA $(292,285), versus $1.92 million in 2025
- ➤Working capital constraints limited growth despite 56.2% gross margins
- ➤Acquisition timeline extended beyond November 16; further progress anticipated in December
Expert Statements
Alex Cunningham, Chief Executive Officer of Cardiff Lexington
“Through the first nine months of 2026, we have stayed focused on our long-term strategy of building Nova Ortho and Spine into a leading healthcare network and expanding access to high-quality care for a patient population that has long been underserved. Revenue was lower than in the prior-year period primarily due to fewer procedures and a lower implicit realization rate on patient case claim settlements. While demand for our services in the markets we serve remains high, working capital constraints has limited our ability to capitalize on opportunities. That said, we retained healthy gross margins of 56.2% of total revenue and are confident that the strategic steps we are taking position us to drive improved operating performance.”
Alex Cunningham, Chief Executive Officer of Cardiff Lexington
“To that end, we continue to make meaningful progress toward the execution of a definitive acquisition agreement under our previously announced letter of intent. Due diligence and negotiations of definitive transaction documents remain ongoing. Importantly, we have received and accepted financing and equity term sheets and are actively advancing the related due diligence, underwriting, and documentation processes. While these additional steps have extended the previously anticipated November 16 timeline, we remain focused on completing the necessary requirements and advancing the transaction toward a definitive agreement, subject to satisfactory due diligence, final financing arrangements, and other customary conditions. We currently anticipate further progress in December, although no definitive execution date has been established.”
Alex Cunningham, Chief Executive Officer of Cardiff Lexington
“In previous years, the Cardiff Lexington model has proven its ability to deliver strong returns on invested capital. Our priorities now are restoring that performance at scale, putting a stronger capital structure behind it and building durable value for our shareholders. We appreciate our shareholders' patience and support.”
LEXINGTON, KY / ACCESS Newswire / November 16, 2026 / Cardiff Lexington Corporation (OTCQX:CDIX), a publicly traded healthcare services holding company focused on orthopedic, spine, and pain management platforms, today announced that it has filed its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 with the U.S. Securities and Exchange Commission.
Alex Cunningham, Chief Executive Officer of Cardiff Lexington, commented, "Through the first nine months of 2026, we have stayed focused on our long-term strategy of building Nova Ortho and Spine into a leading healthcare network and expanding access to high-quality care for a patient population that has long been underserved. Revenue was lower than in the prior-year period primarily due to fewer procedures and a lower implicit realization rate on patient case claim settlements. While demand for our services in the markets we serve remains high, working capital constraints has limited our ability to capitalize on opportunities. That said, we retained healthy gross margins of 56.2% of total revenue and are confident that the strategic steps we are taking position us to drive improved operating performance."
Get started
Create a free account to read the full story.
